Comera SPAC Presentation Deck

Summary Transaction Overview Overview ¹ Ownership¹ Earn-Out Transaction Rationale Use of Proceeds ● ● All existing Comera investors are rolling 100% of their equity into the pro forma company Implied initial equity value of approximately $258.4 million translating into an enterprise value of approximately $151.3 million Comera LIFE SCIENCES 3.15 million shares issuable to Comera's existing stockholders if the pro forma stock price is at or above $12.50 for 20 out of 30 consecutive trading days within 2 years post-closing To execute on and complete new pharmaceutical partnerships and advance internal pipeline Working capital and general corporate purposes Provides Comera with access to public markets, which will help facilitate the development of new or improved subcutaneous formulations of essential biologic medicines through additional growth capital and partnerships Attractive entry point / valuation for investors within biologics market with significant upside potential 1. Pro forma diluted basis at $10.00 per share, assumes no redemptions and excludes impact of unvested stock-based compensation and unvested shares pursuant to the new, to-be-established equity incentive plan, earn-out shares and warrants 28

View entire presentation